NCT05648357View on ClinicalTrials.gov

A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

PHASE4CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

February 26, 2024

Study Completion Date

February 26, 2024

Conditions
Influenza, Human
Interventions
BIOLOGICAL

Fluarix Tetra Vaccine

A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.

Trial Locations (6)

221010

GSK Investigational Site, Varanasi

422002

GSK Investigational Site, Nashik

422003

GSK Investigational Site, Nashik

530002

GSK Investigational Site, Visakhapatnam

590010

GSK Investigational Site, Belagavi

603211

GSK Investigational Site, Kattankulathur

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05648357 - A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India | Biotech Hunter | Biotech Hunter